MarginsXMarginsX
Home › Markets › Health Care › BGM

BGM Group Ltd. (BGM)

BGM trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$8.01
+1.71% on the day
Market cap
$107.0M
Micro cap
Revenue · 2025
$37.9M
+51.1% on 2024
Net income · 2025
-$19.9M
-52.6% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-09-30, https://www.sec.gov/Archives/edgar/data/1779578/000110465926085247/0001104659-26-085247-index.htm. Net income: SEC 20-F (us-gaap:NetIncomeLoss), fiscal year ended 2025-09-30.

Profile

FieldValue
TickerBGM on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryChina
IPO year2021
SEC CIK0001779578
SEC industry codePharmaceutical Preparations
Incorporated inCayman Islands

Financials · 2025

LineValue
Revenue$37.9M
Net income-$19.9M
Operating income-$12.6M
Net margin-52.6%
Operating margin-33.2%
Revenue growth+51.1%
Cash$9.8M
Total assets$433.8M
P/E (computed)Net income was not positive
P/S (computed)2.8×

Warning signs

Cash runway
49.7 months
$9.8M cash at September 30, 2025
Share count, 1 year
+2676.2%
2024-09-30 to 2025-09-30
Going-concern doubt
No
20-F filed July 21, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.20-F 2026-07-21
Cash and burn$9.8M cash; operating cash flow -$593K a quarter.Report 2025-09-30
Shares outstanding13,374,891 (2025-09-30); 14,452,960 a year earlier. the newest SEC cover-page count is from 2025-09-30; shares issued since then are not in these figures.Cover page 2025-09-30
Reverse splits, 3 years2; latest 1-for-30 on 2026-10-01Source 2026-10-01
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorENROME LLP, Singapore, SingaporePCAOB Form AP 2026-07-29
Late filings, 12 months1 NT noticeNT 20-F 2026-01-30
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-09-30
$37.9M-$19.9M-$2.4M$9.8MNo debt tags$37.9M20-F 2026-07-21
FY 2024
2024-09-30
$25.1M-$1.4M$544K$9.8MNo debt tags$25.1M20-F 2026-07-21
FY 2023
2023-09-30
$46.5M-$7.8M$312K$7.5MNo debt tags$46.5M20-F 2026-07-21
FY 2022
2022-09-30
$64.9M$1.1M$12.7M$14.3MNo debt tags$64.9M20-F/A 2025-04-03
FY 2021
2021-09-30
$57.1M$3.2M$345K$10.5MNo debt tags$57.1M20-F 2024-02-15
FY 2020
2020-09-30
$50.0M$5.1M$5.1M$11.9MNo debt tags$50.0M20-F 2023-04-19
FY 2019
2019-09-30
$46.1M$5.9M-$580K$4.6MNo debt tags$46.1M20-F/A 2022-10-13
FY 2018
2018-09-30
$50.4M$5.2M$4.4M$5.6MNo debt tags$50.4M20-F/A 2021-03-09

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
FORM F-3
F-32025-03-07
Latest annual report20-F2026-07-21
Latest quarterly / interim
FORM 6-K
6-K2026-09-24

Source: SEC EDGAR submissions feed, 154 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-4.5%
1 month-24.9%
3 months-12.2%
Year to date-92.9%
1 year-97.1%
From 52-week high-97.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
FHTXFoghorn Therapeutics Inc.$1.79-13.53%$107.3M
ADAGAdagene Inc.$1.60-6.43%$105.7M
CLLSCellectis S.A.$1.04-11.86%$104.5M
DERMJourney Medical Corporation$3.70-14.55%$104.5M
NERVMinerva Neurosciences Inc$2.20-4.35%$109.6M
ORGOOrganogenesis Holdings Inc.$0.8031-0.86%$104.2M
UNCYUnicycive Therapeutics Inc.$3.70+4.23%$103.1M
OKUROnKure Therapeutics Inc.$2.75+4.56%$111.4M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier